CAPRELSA
Drug
GENZYME CORPORATION
Total Payments
$88,928
Transactions
113
Doctors
75
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $4,500 | 27 | 27 |
| 2022 | $1,630 | 14 | 14 |
| 2018 | $53,439 | 17 | 6 |
| 2017 | $29,359 | 55 | 36 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $46,210 | 11 | 52.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $37,879 | 57 | 42.6% |
| Travel and Lodging | $3,914 | 6 | 4.4% |
| Food and Beverage | $921.34 | 38 | 1.0% |
| Education | $3.50 | 1 | 0.0% |
Payments by Type
Research
$46,210
11 transactions
General
$42,718
102 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| LPS14813 | GENZYME CORPORATION | $25,387 | 0 |
| LPS14813-0017 | GENZYME CORPORATION | $9,480 | 0 |
| Phase I/II Trial of Vandetanib (ZD6474, ZACTIMA) in Children and Adolescents with Hereditary Medullary Thyroid Carcinoma | GENZYME CORPORATION | $6,763 | 0 |
| LPS14813-0018 | GENZYME CORPORATION | $2,832 | 0 |
| A randomized, double-blind, placebo-controlled, multi-center, phase III study to assess the Efficacy and Safety of Vandetanib (CAPRELSA) 300 mg in Patients with Papillary or Poorly differentiated Thyr | GENZYME CORPORATION | $1,571 | 0 |
| LPS14813-0010 Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase III Study to Assess the Efficacy and Safety of Vandetanib (Caprelsa) 300 mg in Patients with Papillary or Poorly Differe | GENZYME CORPORATION | $177.00 | 0 |
Top Doctors Receiving Payments for CAPRELSA — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Hematology & Oncology | Philadelphia, PA | $18.22 | 1 |
| , M.D | Otolaryngology | New York, NY | $18.22 | 1 |
| , MD | Nephrology | Willow Grove, PA | $18.22 | 1 |
| , MD | Specialist | Scottsdale, AZ | $17.52 | 1 |
| , MD | Medical Oncology | Fort Worth, TX | $17.05 | 1 |
| , M.D | Surgery | Fort Worth, TX | $17.05 | 1 |
| , MD | Medical Oncology | Erie, PA | $15.91 | 1 |
| , PH.D., D.O | Hematology & Oncology | Cleveland, OH | $15.91 | 1 |
| , M.D | Internal Medicine | Erie, PA | $15.91 | 1 |
| , MD | Hematology & Oncology | Newark, DE | $14.97 | 1 |
| , M.D | Hematology & Oncology | Newark, DE | $14.97 | 1 |
| , M.D., PHD | Hematology & Oncology | Phoenix, AZ | $14.93 | 1 |
| , MD | Hematology & Oncology | Phoenix, AZ | $14.93 | 1 |
| , M.D | Internal Medicine | Wichita, KS | $14.92 | 1 |
| , MD | Endocrinology, Diabetes & Metabolism | Wichita, KS | $14.92 | 1 |
| , M.D | Internal Medicine | Goshen, NY | $14.26 | 1 |
| , MD | Internal Medicine | Goshen, NY | $14.26 | 1 |
| , MD | Internal Medicine | Goshen, NY | $14.26 | 1 |
| , MD | Pulmonary Disease | Goshen, NY | $14.26 | 1 |
| , M.D | Internal Medicine | Middletown, NY | $14.26 | 1 |
| , M.D | Hematology & Oncology | Manasquan, NJ | $13.08 | 1 |
| , M.D | Hematology & Oncology | Phoenix, AZ | $12.74 | 1 |
| , M.D | Endocrinology, Diabetes & Metabolism | Williamsburg, VA | $11.04 | 1 |
| , D.O | Hematology & Oncology | Fresno, CA | $10.71 | 1 |
| , M.D | Hematology & Oncology | Fresno, CA | $10.71 | 1 |
Ad
Manufacturing Companies
- GENZYME CORPORATION $88,928
Product Information
- Type Drug
- Total Payments $88,928
- Total Doctors 75
- Transactions 113
About CAPRELSA
CAPRELSA is a drug associated with $88,928 in payments to 75 healthcare providers, recorded across 113 transactions in the CMS Open Payments database. The primary manufacturer is GENZYME CORPORATION.
Payment data is available from 2017 to 2024. In 2024, $4,500 was paid across 27 transactions to 27 doctors.
The most common payment nature for CAPRELSA is "Unspecified" ($46,210, 52.0% of total).
CAPRELSA is associated with 6 research studies, including "LPS14813" ($25,387).